31 Mar 2020
Assets5.30
Total Income12.77
Profit After Tax0.81
NET Worth2.02
Reserves and Surplus2.01
Total Borrowing0.36
At a glance
Updated 2026-09-17The shares listed at ₹1,711.25, a 39.24% move from the issue price. Remus Pharmaceuticals is a SME IPO with an issue size of ₹47.69 crore, proposed for listing on NSE SME. The offer opens on 17th May 2023 and closes on 19th May 2023. The issue structure includes a fresh issue of ₹45.29 crore. The current listing schedule points to 29th May 2023.
Issue details
Listing atNSE SME
Issue typeBook Build Issue
Issue size₹47.69 Cr
Fresh issue₹45.29 Cr
Face value₹10
Price band₹1,150.00–₹1,229.00
Allotment24th May 2023
Listing29th May 2023
Listing performance
Full performance ↗Issue price₹1,229.00
Listing price₹1,711.25
Current price—
Listing gain39.24%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹575.00
GMP / upper price46.79%
Est. listing₹1,804.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens17th May 2023
Closes19th May 2023
Allotment24th May 2023
Refund25th May 2023
Demat26th May 2023
Listing29th May 2023
Subscription demand
Full bidding ↗Total61.53×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 100 | ₹122,900 |
Company
Incorporated2015
Use of proceeds
| Object | Amount |
|---|---|
| To Meet Working Capital Requirements | ₹30.30 Cr |
| Funding investments for acquisitions and general corporate purposes | ₹16.38 Cr |
| Public Issue Expenses | ₹1.00 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue33.61₹ Cr · +32.1% vs prior year
PAT6.44₹ Cr · +90.0% vs prior year
Assets33.53₹ Cr · +110.7% vs prior year
Net Worth17.12₹ Cr · +166.3% vs prior year
Borrowing9.47₹ Cr · +4,884.2% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2021
Assets11.05
Total Income19.22
Profit After Tax1.03
NET Worth3.05
Reserves and Surplus3.04
Total Borrowing0.28
31 Mar 2022
Assets15.91
Total Income25.44
Profit After Tax3.39
NET Worth6.43
Reserves and Surplus5.43
Total Borrowing0.19
31 Dec 2022
Assets33.53
Total Income33.61
Profit After Tax6.44
NET Worth17.12
Reserves and Surplus16.04
Total Borrowing9.47
KPIs
| KPI |
|---|
| ROE |
| ROCE |
| Debt / Equity |
| RoNW |
| PAT Margin |
Valuation & shareholding
Pre-IPO EPS33.86
Pre-IPO P/E21.09
Promoter holding pre92.82%
Promoter holding post68.37%
Market cap₹181.03 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Remus Pharmaceuticals IPO | — | 21.09 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Speciality Medicines IPO | — | 10.49 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| To Meet Working Capital Requirements | ₹30.30 Cr |
| Funding investments for acquisitions and general corporate purposes | ₹16.38 Cr |
| Public Issue Expenses | ₹1.00 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- Beeline Capital Advisors Pvt.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-17.
IPO UPDATE ALERTS
Register for IPO Updates →Track Remus Pharmaceuticals without missing an update
Register for subscription, GMP, allotment and listing notifications.